Supported by

Catalogue of collaboration profiles

back to list

Catalent Pharma Solutions

Frankland Road, Blagrove
ZIP Code
United Kingdom

Company Profile:
Catalent Pharma Solutions offers a wide variety of development, drug delivery, manufacturing, and packaging services. Within our specialist biotechnology services division, Catalent’s Middleton Wisconsin facility offers its proprietary GPEx® technology platform for external collaboration. GPEx® is a proven expression solution for the development and production of high titre, stable mammalian cell lines for the manufacture of recombinant antibodies and proteins. The technology has enabled the development of over 150 monoclonal antibody cell lines and over 40 recombinant proteins for our partners. Numerous GPEx® cell lines are the progenitors of products in the clinic with one product already on the market. GPEx® is equally effective in the production of novel biologic entities and in the development of biosimilar entities - our in-house portfolio of high expression cell lines expressing selected biosimilar products is available for partnering.

GPEx® technology platform

What we offer:
Catalent’s GPEx® technology consistently produces high expressing, stable and clonal cell lines in serum protein free media in less than five months after receipt of cDNA. The reliability and short timeline of GPEx® projects and allows clients to turn product into revenue faster than conventional methods, vastly reducing the cost of goods. In addition to GPEx® cell line engineering, Catalent’s Middleton facility carries out cell banking, process development, analytical development and cGMP manufacturing services utilizing stirred tank, stainless steel bioreactors for products produced from any mammalian cell line. These projects are supported by the viral clearance, bioassay / clinical assay development, fill/finish and additional capabilities provided within the Catalent group..

What are we looking for:
Catalent is interested in meeting potential clients looking for cell line engineering services, and/or cGMP manufacturing services (including cGMP production from mammalian cell lines produced by other technologies). We would also be interested in hearing from partners looking to accelerate their biosimilar development pipeline with our advanced set of pre-validated products. For more information, contact our Business Development Group at (email) or visit our website at For further information about the breadth of expertise at other Catalent facilities visit us at

Collaboration sought:
  • Research & Development
  • Technical Co-operation
  • Joint Venture Agreement
  • Manufacturing Agreement
  • Licence
  • Commercial Agreement


Daniel Ozanne

Account Director
back to list


Enterprise Europe ScotlandAboleo LtdAccuro BiologicsAlliance BootsBeta TechnologyBitWiseFW Medical LLPInnova Partnerships LtdInterface-The knowledge connection for businessMarks and Clerk LLPMcClure Naismith LLPThe Medical Device Company LtdQuantics Consulting LtdScottish Health InnovationsPharmalinksSistemic LtdStrathclyde Institute of Medical DevicesSynthetic Nanomachines LtdTissue SolutionsUniversity of AberdeenEllis IP LtdPharmacells LtdCeltic CatalystsPharmaceutical eConsultingWeatherologyControlled TherapeuticsSphere Fluidics LimitedHighland Clinical Research FacilityMoorfields PharmaceuticalsEdinburgh Science Trianglebeocarta LtdRostiShore DesignPomBioTech GmbHIMG Innovations-Management  GmbH/ Enterprise Europe NetworkThe Eurotactics ConsultancyIBA GmbHSGS Life Science ServicesOnorach  ClinicalWideblueEnterprise Europe YorkshireAptuit ConsultingMosaigen/Endeavour CapitalEscubed LtdEulysis Ltd.Raumedic LtdCatalent Pharma SolutionsEscubed LtdUniversity of Aberdeen Research and InnovationSPRI - Basque Enterprise Europe NetworkLicentia LtdTake The WindRoslin CellabMoredun ScientificEnterprise Europe East of EnglandAvantiCell ScienceXeroshield Ltd.ImmunoSolv LimitedLeoben Research LimitedPRAXI / HELP-FORWARD Network &The Hellenic BioClusterEMBIO Diagnostics Ltd

© 2010 ConVerve GmbH | all rights reserved